Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Hypertens. 2015 Oct 16. pii: hpv172. [Epub ahead of print]

Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial.

Author information

1
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA; chenx484@umn.edu.
2
Columbia University Department of Medicine, Division of Cardiology, New York, New York, USA;
3
Columbia University Department of Medicine, Division of Cardiology, New York, New York, USA; Columbia University School of Nursing, New York, New York, USA;
4
Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA;
5
SUNY Downstate Medical Center, Brooklyn, New York, USA;
6
Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA;
7
The Veterans Administration Medical Center, Washington, DC, USA;
8
Endocrinology, Diabetes, Bone and Mineral Disorders Division, Henry Ford Hospital, Detroit, Michigan, USA;
9
Section of Endocrinology and Metabolism, University of Manitoba, Winnipeg, Manitoba, Canada;
10
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA;
11
Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Division of Public Health Sciences, Winston-Salem, North Carolina, USA; Department of Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Abstract

BACKGROUND:

There are no proven strategies to prevent atrial fibrillation (AF) in patients with type 2 diabetes (T2DM). We compared standard blood pressure (BP) lowering vs. intensive BP lowering in reducing incidence of AF or P-wave indices (PWI-ECG markers of left atrial abnormality that are considered intermediate phenotypes of AF) in patients with T2DM.

METHODS:

We analyzed data from the ACCORD BP trial-a randomized controlled nonblinded trial (2001-2009) which randomized patients with T2DM and systolic BP (SBP) 130-180mm Hg on ≤3 antihypertensive medications aged 40-79 years with cardiovascular disease (CVD) or aged 55-79 years with subclinical CVD or ≥2 CVD risk factors to standard BP lowering (SBP <140mm Hg) vs. intensive BP lowering (SBP <120mm Hg). The primary outcome was a composite of incident AF and PWI.

RESULTS:

Data from 3,087 participants (mean age, 62.2 years; women, 48.2%; non-White, 39.2%) were analyzed. During a mean follow-up of 4.4 years, the primary outcome occurred in 1,063 participants (incidence rate, 84.5 per 1,000 person-years in the standard-therapy group vs. 73.9 per 1,000 person-years in the intensive-therapy group). The adjusted hazard ratios (95% confidence intervals) of intensive-therapy group for the primary outcome and for incident PWI alone were 0.87 (0.77-0.98), P = 0.02 and 0.87 (0.76-0.98), P = 0.02, respectively. The effect of intensive therapy on the incidence of AF alone did not reach statistical significance.

CONCLUSIONS:

In patients with T2DM, intensive BP lowering reduces the incidence of the composite outcome of AF and PWI, suggesting a potential benefit from stringent BP control in patients with T2DM.clinical trials registrationTrial Number NCT00000620.

KEYWORDS:

P-wave indices; atrial fibrillation; blood pressure; diabetes mellitus; hypertension; left atrial abnormality; randomized controlled trial

PMID:
26476086
PMCID:
PMC5055733
[Available on 2017-11-01]
DOI:
10.1093/ajh/hpv172
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center